Melanoma trials recruiting in Arizona

All Melanoma trials nationally

Cities in Arizona

Recruiting trials in Arizona

• A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
  NCT04370587 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Gilbert
• A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
  NCT07070232 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Phoenix
• A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
  NCT07636785 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Arizona: Scottsdale
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
  NCT05914116 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Tucson
• A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
  NCT06581406 · Phase: Phase 2, Phase 3 · Ages: No age limits stated · Sex: All (male and female) · Arizona: Scottsdale
• A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
  NCT06246916 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Chandler, Gilbert, Tucson
• A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
  NCT05824975 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Scottsdale
• Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
  NCT06418204 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Kingman, Phoenix
• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
  NCT05136196 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Phoenix
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  NCT05334069 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female) · Arizona: Kingman, Phoenix
• DESTINY-PANTUMOUR04
  NCT07124000 · Phase: Not specified · Ages: 18 Years to 130 Years · Sex: All (male and female) · Arizona: Bullhead City, Casa Grande
• DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
  NCT07288112 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Gilbert, Scottsdale
• Dabrafenib and/or Trametinib Rollover Study
  NCT03340506 · Phase: Phase 4 · Ages: 18 Years to 100 Years · Sex: All (male and female) · Arizona: Scottsdale
• Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
  NCT03567889 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Phoenix
• Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
  NCT07136181 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Scottsdale
• IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
  NCT06112314 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Tucson
• Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
  NCT03860883 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Gilbert, Phoenix
• Neoadjuvant Darovasertib in Primary Uveal Melanoma
  NCT07015190 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Scottsdale
• ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
  NCT05059444 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Chandler
• Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
  NCT06249048 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Scottsdale
• Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
  NCT07751042 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Scottsdale
• Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
  NCT04787042 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Scottsdale
• Project: Every Child for Younger Patients With Cancer
  NCT02402244 · Phase: Not specified · Ages: Up to 25 Years · Sex: All (male and female) · Arizona: Kingman, Mesa, Phoenix, Tucson
• Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
  NCT06814496 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Arizona: Tucson
• SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
  NCT06743126 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Phoenix, Scottsdale
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
  NCT03452774 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Arizona: Scottsdale
• Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
  NCT06697301 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Chandler
• Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
  NCT06425926 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Scottsdale
• Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
  NCT07287917 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Tucson
• Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
  NCT04282044 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Scottsdale
• Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
  NCT06585410 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Phoenix, Scottsdale, Tucson
• Symptom Management and Survivorship Plus Coaching for Advanced Cancer Survivors and Their Caregivers
  NCT07415564 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Tucson
• TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
  NCT04485013 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Tucson
• Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
  NCT05549297 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Phoenix
• Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
  NCT06500455 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Tucson
• VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
  NCT06264180 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · Arizona: Gilbert